Uncovering the mechanisms of action of an antiviral bacterium

This project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function.

Subsidie
€ 1.500.000
2023

Projectdetails

Introduction

Animals and microbes interact in intricate ways. Wolbachia, a common intracellular insect symbiont, can manipulate reproduction and protect hosts from viruses. Thus, Wolbachia is an asset in the control of insect-borne diseases. However, as Wolbachia cannot be cultured outside of host cells or genetically manipulated, the mechanisms of its antiviral phenotype remain poorly understood, and this inhibits wider exploitation.

Research Objectives

I have been working to remedy these deficiencies, and now stand poised to discover the mechanisms of Wolbachia-conferred antiviral protection by answering the following questions:

1. Origin of Protection

Where does the protection originate? Up to now, mechanisms of protection have been studied in whole organisms, often lacking resolution, or in cultured cells, which lack emergent properties. I will identify tissues and cell types of the host where protection starts. To do this, I will:

  • a) Quantify titers of Wolbachia and virus at early time points post-viral infection in insect tissues.
  • b) Measure gene expression of host and microbes to identify candidates for further molecular characterization.
  • c) Test the extent of the utility of widely adopted, yet unvalidated, cell-culture models of antiviral protection.

2. Wolbachia Genes and Protection

Which Wolbachia genes effect protection? Wolbachia research has historically been impeded by a lack of tools to study gene function. Here, I will deploy antisense technology, which I have recently developed, to interrogate the function of candidate Wolbachia genes in the native system. I will also engineer new methods to target Wolbachia genes and proteins, based on my data on cell-penetrating peptide-mediated delivery of bioactive cargo to Wolbachia.

Expected Outcomes

This project has two major outcomes: it will uncover Wolbachia factors responsible for Wolbachia-conferred antiviral protection, and it will transform Wolbachia and symbiosis research by creating tools to study symbiont gene function.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.500.000
Totale projectbegroting€ 1.500.000

Tijdlijn

Startdatum1-1-2023
Einddatum31-12-2027
Subsidiejaar2023

Partners & Locaties

Projectpartners

  • UNIWERSYTET JAGIELLONSKIpenvoerder

Land(en)

Poland

Vergelijkbare projecten binnen European Research Council

ERC Starting...

Exploring the Prokaryotic-Eukaryotic Conservation of Antiviral immunity: from bacterial immune systems to novel antiviral drugs

This project aims to map bacterial antiviral immunity and discover novel anti-phage compounds, potentially transforming our understanding of prokaryotic immune systems and leading to new antiviral therapies.

€ 1.496.500
ERC Advanced...

PIWI-interacting RNAs at the interface of virus-host conflicts in Aedes aegypti mosquitoes

This project aims to explore the role of piRNAs in protecting mosquito germlines from viruses, enhancing understanding of virus-host interactions and developing strategies for mosquito-borne virus resistance.

€ 2.500.000
ERC Advanced...

Evolutionary immunology: using insect models to unravel STING-dependent conserved and innovative antiviral strategies

This project aims to explore antiviral gene diversity in insects, leveraging cGAMP-triggered responses in Drosophila to identify novel antiviral mechanisms for potential therapeutic applications.

€ 2.396.099
ERC Starting...

Archaeal Virology: unravelling the mechanisms of interviral warfare

This project aims to investigate viral mechanisms that enable competition among viruses infecting archaea, with potential applications in enhancing human health and reducing methane emissions.

€ 1.500.000
ERC Advanced...

Molecular dissection of viral genomes for future antiviral treatments

This project aims to identify and characterize virus-encoded transmembrane proteins as novel pharmaceutical targets for antiviral drug discovery and treatment of viral infections.

€ 2.420.301